Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

Vikrant V. (Vik)  Sahasrabuddhe

Vikrant V. (Vik) Sahasrabuddhe, MBBS, MPH, DrPH

Research Associate Professor of Medicine (Epidemiology)

Contact Information:

Vanderbilt Institute for Global Health
2525 West End Avenue, Suite 750
Nashville TN 37203-1738

Clinical Research Description

Dr. Vikrant Sahasrabuddhe is a clinical epidemiologist and cancer prevention researcher who received his medical degree from the University of Pune in India, his master's and doctorate degrees in public health from the University of Alabama at Birmingham, and completed fellowship training in epidemiology at the Johns Hopkins University Bloomberg School of Public Health and at the National Cancer Institute. Dr. Sahasrabuddhe has served on the faculty at the Vanderbilt University School of Medicine since 2005, and is currently based as a Senior Biomedical Scientist-Intergovernmental Personnel Act Mobility Program detailee in the Division of Cancer Prevention at the National Cancer Institute, National Institutes of Health. Dr. Sahasrabuddhe has conducted both clinic-based and population-based research on infection-associated cervical, anogenital, and hepatobiliary cancers with high or rising incidence and mortality burden. As Program Director of the Vanderbilt Institute for Global Health's HIV-Cervical Cancer Prevention Program, he has spearheaded clinical and public health efforts for the development, implementation, and evaluation of cervical cancer prevention interventions in global resource constrained settings, through collaborative research, training, and service initiatives. Dr. Sahasrabuddhe's published works and research interests encompass a broad spectrum of clinical and translational research areas related to cancer prevention, including the evaluation of novel and low-cost cervical cancer screening approaches (visual imaging methods and HPV-based biomarkers), optimizing dosing and delivery of HPV vaccination, evaluating the repurposing of commonly-used medications for cancer prevention indications, measuring the effectiveness of scaling-up of cervical cancer prevention implementation programs, and demonstrating synergies in the horizontal integration of vertical public health initiatives. Dr. Sahasrabuddhe led the initial development, and continues to advise the Cervical Cancer Prevention Program in Zambia-African Center of Excellence for Women's Cancer Control, the largest such program implementation initiative in sub-Saharan Africa. He serves as Protocol Co-Vice Chair of a NIH-funded multi-country randomized clinical trial evaluating a 'test-and-treat' approach for cervical cancer prevention in high-risk HIV-infected women in India, South Africa, Malawi, Botswana, Zimbabwe, Haiti, and Peru. In addition, he has collaborated on, and advised graduate and postdoctoral trainee-led research studies in India, Zambia, China, Thailand, and Tanzania.